This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Liraglutide reduced calorie intake but did not improve overall diet quality compared to dietitian-guided caloric restriction. The caloric restriction group made bigger improvements in protein intake and added sugar reduction.
Why it matters
GLP-1 drugs help people eat less, but they do not necessarily help people eat better. Adding nutrition counseling to GLP-1 treatment may be important for long-term health outcomes beyond weight loss.
The numbers in context
70 participants (69% female, 83% white, mean BMI 39.5). 2:1:1 randomization. Liraglutide 1.8 mg/day for 14 weeks. Significant differences in protein (p=0.037), carbs (p=0.019), and added sugar (p=0.002) changes across groups.
How the study worked
Secondary analysis of a randomized controlled trial. 24-hour dietary recall pre- and post-intervention. Compared liraglutide, dietitian-guided caloric restriction (-390 kcal/day), and DPP4 inhibitor (100 mg/day).
Who was studied
Adults with obesity and prediabetes
What this study cannot tell us
Small sample (70 patients). Single 24-hour recall may not capture habitual intake. Short duration (14 weeks). Secondary analysis, not powered for dietary outcomes.
Read the original research
The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial.
Diabetes, obesity & metabolism, 27(7), 3725-3735
Citation
Richardson, Kelli M; Schembre, Susan M; Jospe, Michelle R; Widmer, Annaliese; Silver, Heidi J. (2025). The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial.. Diabetes, obesity & metabolism, 27(7), 3725-3735. https://doi.org/10.1111/dom.16395